Investigation of the blood levels at a reduced dose of erlotinib with the addition of ritonavir compared to the normal dose of erlotinib
Ontology highlight
ABSTRACT: Primary objectives: Effect of the highly potent CYP3A4 inhibitor ritonavir on the pharmacokinetics (PK) of erlotinib, measured as AUC0-24h, AUCmean, Cmax and Cmin
Primary endpoints: The effect of the highly potent CYP3A4 inhibitor ritonavir on the pharmacokinetics (PK) of erlotinib, measured as AUC0-24h, Cmax and Cmin.
DISEASE(S): Non-small Cell Lung Cancer Stage Iv,Advanced Egfr Mutation Positive Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer And Biliary Cancer,Gevorderd Egfr Mutatie Positief Niet-kleincellig Longkanker, Pancreascarcinoom, Colorectaal Kanker En Galwegkanker
PROVIDER: 2538815 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA